Origin House Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2018

• On April 1, 2019, the Company entered into a definitive agreement to be acquired by Cresco Labs for $1.1 billion, creating a North American cannabis powerhouse.
• Record Q4 revenue of $7.9 million; + 19% vs. Q3 2018 and +638% vs. Q4 2017, driven by distribution revenues and product sales across all cannabis product categories.
• Acquired Kaya Manufacturing, Alta Supply, RVR Distribution, FloraCal Farms and 180 Smoke in 2018 to create a footprint today comprised of 6 licenses, 8 facilities and over 350 employees in California and Canada, with pro-forma revenue of $37.4 million. Pro-forma revenue reached $48.7 million with the acquisition of 180 Smoke in Q1 2019.
• Integrated two of the largest and most important distributors in California – RVR Distribution and Alta Supply – now operating as a statewide network under the Continuum banner with more than 50 brand relationships and over 1,000 SKUs in more than 500 dispensaries and greater than 60% penetration¹ in licensed dispensaries in California.
• The Company's Brand Accelerator Program initiated in Q4 2018 and other strategic brand partnerships have added dynamic brands to the platform including King's Garden, Henry's Original, Utopia Cannabis, Pacific Remedy, Kurvana, Humboldt's Finest, Viola Brands and Papa's Herb.
• Exited the year with a cash position of $69.2 million as of December 31, 2018.

OTTAWA, April 29, 2019 /CNW/ - CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) ("Origin House" or the "Company"), a leading North American cannabis products and brands company, announced today the Company's financial results for the three months and year ended December 31, 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated. Origin House's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Marc Lustig, CEO of Origin House, commented, "During 2018, Origin House delivered demonstrable value creation for shareholders through organic execution, judicious acquisitions and the crystallization of value embedded in non-core assets. Throughout the year, we continued to aggressively build our platform of brands and distribution capability focused in California, and this culminated in reaching a definitive agreement to be acquired by Cresco Labs for $1.1 billion on April 1, 2019. This partnership is just the beginning of our journey together. The combined entity will be a U.S. distribution powerhouse, with a growing portfolio of over 50 brands on the shelves of over 725 dispensaries across 11 states. In the coming months we will work side-by-side with the Cresco team to accelerate recognition and sales for our combined brand portfolios across the U.S., and in the process, continue to build substantial shareholder value."

Afzal Hasan, President and General Counsel of Origin House added, "We are very pleased with the performance our team generated in 2018. We spent the past 12 months successfully implementing our strategy to build a platform of premium brands by creating the top distribution and brand support platform in California. Our team executed and successfully integrated five acquisitions during the year, while adding several key experiential brands to our Brand Accelerator and distribution platform. In March 2019, with the integration of our two distribution companies under the Continuum banner, Origin House now controls one of the top state-wide distribution networks in California. With 2018's regulatory growing pains behind us and a recent commitment on the part of the government to redouble its efforts to quash the still-thriving illegal cannabis market in the state, Origin House is off to a running start in early 2019. Our pipeline of potential brand partners is more robust than at any point in our recent history and our ability to leverage a fully integrated network, positions us to win California while generating strong performance for our brand partners as well as for shareholders."

_____________________
1	Based on the percentage of licensed cannabis micro-businesses and storefronts serviced over the past 9 months.

Financial Highlights – Q4 and Year Ended – 2018

The following are the major financial highlights of Origin House's operating results for the year ended December 31, 2018, compared to the year ended December 31, 2017:

• Revenues were $18.7 million as compared to $3.1 million, an increase of 507%;
• Gross margin, excluding fair value items, was $1.5 million as compared $0.9 million, an increase of 67%;
• Pro-forma revenues were $37.4 million as of December 31, 2018 and were $48.7 million with the acquisition of 180 Smoke on February 19, 2019;
• Operating expenses were $36.2 million as compared to $13.3 million, an increase of 173%;
• Adjusted EBITDA profit of $3.4 million as compared to adjusted EBIDTA profit of $4.1 million; and
• Repurchased 975,900 of the Company's common shares, at a weighed average price of $6.13 per share and a total cost of $6.0 million.

The following are the major financial highlights of Origin House's operating results for the three months ended December 31, 2018, compared to the three months ended December 31, 2017:

• Revenues were $7.9 million as compared to $1.1 million, an increase of 638%;
• Gross margin, excluding fair value items, was $0.2 million as compared $0.1 million, an increase of 87%;
• Operating expenses were $15.4 million as compared to $4.6 million, an increase of 233%; and
• Adjusted EBITDA loss of $1.9 million as compared to adjusted EBIDTA profit of $7.9 million.

The following is a summary of key balance sheet totals as at December 31, 2018, compared to December 31, 2017:

• Cash was $69.2 million as compared to $4.5 million an increase of 1430%;
• Total assets of $230.7 million as compared to $46.1 million, an increase of 400%;
• Current assets of $86.0 million as compared to $7.9 million, an increase of 982%;
• Current liabilities of $26.2 million as compared to $2.1 million, an increase of 1126%; and
• Long-term debt financing of $16.0 million as compared to $2.3 million, an increase of 610%.

Corporate Highlights Subsequent to the Quarter ended December 31, 2018

For a more comprehensive overview of these recent developments, please refer to Origin House's Management's Discussion and Analysis of the Financial Condition and Results of Operations for Three Months and Year Ended December 31, 2018.

• On March 31, 2019, Origin House and Cresco Labs Inc. ("Cresco Labs") entered into a definitive agreement (the "Sale Agreement") under which Cresco Labs will acquire all the issued and outstanding shares of Origin House (the "Origin House Shares") (the "Transaction"). Under the terms of the Sale Agreement, holders of common shares of Origin House will receive 0.8428 subordinate voting shares of Cresco Labs (the "Cresco Labs Shares") for each Origin House Share. The Transaction represents total consideration of approximately $1.1 billion on a fully-diluted basis. The transaction is expected to close in June 2019.
• On March 26, 2019, Resolve Digital Health Inc. ("Resolve") announced that it was approved by Health Canada for a Medical Device License for cannabis use. As at December 31, 2018, Origin House held 14,176,738 shares, representing 25.6% issued and outstanding shares of Resolve.
• On March 5, 2019, the Company entered into an agreement with Mendocino-based cannabis producer, Henry's Original ("Henry's"), whereby the Company will be the exclusive distributor of Henry's Original products in California. In addition, the Company provided a convertible bridge loan of US$2.5 million to Henry's for expansion, including construction and operation of additional cultivation sites for the 2019 growing season.
• On February 25, 2019, the Company elected to exercise its rights under the indenture dated July 12, 2018, governing the Company's 8% unsecured convertible debentures due July 12, 2021 to convert the principal amount of the outstanding Debentures to common shares of the Company.
• On February 19, 2019, the Company completed the acquisition of 180 Smoke and its affiliates ("180 Smoke"), an online and retail Canadian vape operator. The Company expects the acquisition to result in a retail revenue stream and footprint within Canada. Pro forma revenue for 180 Smoke is $11.3 million.
• On February 14, 2019, a 69% owned Origin House subsidiary, Trichome Financial Corp. ("Trichome"), announced the commencement of a non-brokered private placement of subscription receipts in connection with its proposed reverse take-over of 22 Capital Corp. Trichome intends to use the proceeds of the financing to fund Trichome's growing pipeline of cannabis sector credit opportunities and for general corporate purposes.
• On February 13, 2019, the Company signed a memorandum of understanding ("MOU") to commence exclusive distribution of Kurvana products across Northern California. As part of the MOU, the parties have also agreed to explore the transition of distribution in Southern California, subject to fulfilment of mutually acceptable conditions. In addition, Origin House has agreed to provide strategic financing of up to US$10 million to Kurvana under a promissory note.
• On February 4, 2019, the Company provided strategic financing of US$704,000 to Humboldt's Finest Farms ("Humboldt"), an alliance of heritage cannabis farms representing Humboldt County. The funds were advanced towards the forward purchase of Humboldt's Finest cannabis and cannabis products at a discount to wholesale prices.
• On January 30, 2019, the Company provided additional strategic financing of US$750,000 and signed an exclusive distribution agreement with Utopia Cannabis ("Utopia"), a California-based cannabis brand.
• On January 28, 2019, the Company's wholly-owned subsidiary RVR entered an exclusive agreement with Viola Brands ("Viola"), an ultra premium flower, pre-rolls, extract and vapes company, for the state of California. RVR will be the exclusive distributor of all Viola products in California. The Company will also manufacture Viola's products, either in house or through third-party manufacturers.
• On January 15, 2019, the Company signed a binding term sheet with Alternative Medical Enterprises LLC ("AltMed") to convert the Company's 3.5% royalty interest (the "MÜV Royalty") on the sale of AltMed's MÜV branded products ("MÜV") to AltMed equity. In converting its MÜV Royalty to AltMed equity, the Company received 125 equity units in AltMed as well as cash consideration. This transaction increased the Company's equity stake in AltMed to 5.1%.
• On January 15, 2019, CRHC Holdings Corp. ("CRHC"), a wholly owned subsidiary of the Company, completed the sale of 51% of its 10% equity interest in Bodhi Research Inc. ("Bodhi") to Green Relief. Green Relief purchased 51% of all outstanding stock of Bodhi, which included the 51% of CRCH's equity stake. As consideration for the sale, CRHC received $1.7 million in Green Relief common shares.

Results of Operations (Summary)
The following tables set forth consolidated statements of financial information for year ended December 31, 2018, and December 31, 2017. For further information regarding the Company's financial results for these periods, please refer to the Company's Management's Discussion and Analysis for the periods ended December 31, 2018 and December 31, 2017 and the Company's Financial Statements for the periods ended December 31, 2018 and December 31, 2017, published on Origin House's issuer profile on SEDAR at www.sedar.com and the Company's website at www.OriginHouse.com.

	December  31, 2018	December 31, 2017	Change
Selected statement of financial position data
Cash and cash equivalents	$       69,206,193	$          4,522,644	$       64,683,549
Working capital	59,810,772	5,813,705	53,997,067
Total investments (1)	21,741,531	26,674,288	(4,932,757)
Total assets	230,698,045	46,139,757	184,558,288
Long term and convertible debt	16,026,098	2,258,467	13,767,631
Shareholders' equity	172,972,132	40,468,344	132,503,788
Dividends, per share	-	-	-
(1) This represents the sum of investments, royalty investments, and interests in equity method investees

	Years ended December 31
	2018	2017
Consolidated statements of comprehensive loss
Revenue	$            18,692,950	$              3,077,969
Gross margin, excluding fair value items	1,507,951	905,629
Operating expenses	36,238,129	13,260,897
Loss from operations	(35,146,799)	(12,355,268)
Net loss	(9,033,733)	(9,065,492)
Other expense	6,718,806	(929,957)
Total comprehensive loss	(2,314,927)	(9,995,449)
Net loss attributable to owners of the Company	(8,413,927)	(8,891,490)
Net loss per common share - basic & diluted	(0.15)	(0.21)
Weighted average common shares - basic & diluted	54,526,935	41,439,567

Revenue by Type

	Years ended December 31		% change
	2018	2017
California operations segment
Product sales	$            17,249,799	$                  977,028	1666%
Corporate segment
Services	757,350	859,605	(12%)
Royalties	370,413	1,103,645	(66%)
Interest income	301,162	137,691	119%
Other Income	14,226	-
Total	$            18,692,950	$              3,077,969	507%

Cost of Sales by Revenue Type

	Years ended December 31		% change
	2018	2017
California operations segment
Cost of product sales	$            15,999,390	$              1,391,896	1049%
Corporate segment
Cost of services	323,929	218,479	48%
Cost of royalties	861,680	561,965	53%
Total	$            17,184,999	$              2,172,340	691%

Gross Profit by Revenue Type

	Years ended December 31		% change
	2018	2017
California operations segment
Products	$              1,250,409	$                (414,868)	401%
Corporate segment
Services	433,421	641,126	(32%)
Royalties	(491,267)	541,680	(191%)
Interest	301,162	137,691	119%
Other Income	14,226	-
Total	$              1,507,951	$                  905,629	67%

Gross Margin by Revenue Type

	Years ended December 31		% change
	2018	2017
California operations segment
Products	7%	(42%)	117%
Corporate segment
Services	57%	75%	(23%)
Royalties	(133%)	49%	(370%)
Interest	100%	100%	-
Other Income	100%	-	-
All Types	8%	29%	(73%)

Operating Expenses

	Years ended December 31
	2018	2017	Change
Sales and marketing	$              8,328,926	$              1,456,874	472%
Research and product development	1,101,553	931,053	18%
General and administrative	23,222,729	10,076,087	130%
Amortization of intangibles	3,584,921	796,883	350%
Total	$            36,238,129	$            13,260,897	173%

Non-IFRS Financial Measures
The Company has provided unaudited pro forma financial information, which assumes that closed mergers and acquisitions in 2018 are included in the Company's financial results as of the beginning of fiscal 2018. EBITDA and Adjusted EBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.

Adjusted EBITDA¹

	Year ended December 31
	2018	2017
Add (Subtract)
Net loss for the period	$                    (9,033,733)	$             (9,065,492)
Depreciation of property and equipment	608,012	178,821
Amortization of intangible assets	3,584,921	796,883
Amortization of royalty investments	848,811	493,961
Interest expense	3,527,528	467,957
Interest income	(301,162)	(137,691)
Current income taxes	623,126	105,021
Deferred income tax recovery	(1,951,802)	(1,605,823)
EBITDA	(2,094,299)	(8,766,363)
Additional expense related to letter of intent transactions	-	204,060
Bad debt expense – Cascadia royalties	-	919,481
Gain on sale of equipment	(24,672)	(91,674)
Gain on settlement of interests at acquisition	(1,096,189)	-
Impairment (recovery) of convertible notes receivable	(4,146)	559,845
Impairment of intangible assets & goodwill	-	2,335,000
Disposal of intangible assets	159,032	-
Impairment of loans and advances	359,947	3,776,081
Impairment of royalty investments	-	1,014,211
Post combination remuneration	354,266	-
Realized fair value amounts included in inventory sold	2,028,238	-
Unrealized fair value gain on growth of biological assets	(1,611,617)	-
Impairment (recovery) on Achelois Inventory	(441,871)	422,386
Share-based compensation	5,228,103	3,583,881
Transaction costs on acquisitions	536,840	-
Unrealized loss on embedded derivatives	-	110,965
TOTAL ADJUSTED EBITDA	$                     3,393,632	$              4,067,873
Weighted average number of common shares outstanding - basic & diluted	54,526,935	41,439,567
ADJUSTED EBITDA per share - basic & diluted	0.06	0.10

	Three months ended December 31
	2018	2017
Add (Subtract)
Net loss for the period	$             (6,175,650)	$             (1,248,719)
Depreciation of property and equipment	307,940	41,091
Amortization of intangible assets	1,433,782	195,470
Amortization of royalty investments	28,258	82,816
Interest expense	1,680,988	345,903
Interest income	(71,117)	(78,003)
Current income taxes	315,536	105,021
Deferred income tax recovery	(1,505,038)	(1,375,121)
EBITDA	(3,985,301)	(1,931,542)
Additional expense related to letter of intent transactions	-	(10,495)
Bad debt expense – Cascadia royalties	-	919,481
Gain on sale of equipment	(24,672)	-
Gain on settlement of interests at acquisition	2,185	-
Impairment (recovery) of convertible notes receivable	(4,146)	559,845
Impairment of intangible assets & goodwill	-	2,335,000
Disposal of intangible assets	159,032	-
Impairment of loans and advances	359,947	3,776,081
Impairment of royalty investments	-	1,014,211
Post combination remuneration	354,266	-
Realized fair value amounts included in inventory sold	866,767	-
Unrealized fair value gain on growth of biological assets	(659,923)	-
Impairment (recovery) on Achelois Inventory	(501)	422,386
Share-based compensation	1,005,540	1,084,525
Transaction costs on acquisitions	-	-
Unrealized loss on embedded derivatives	-	(258,071)
TOTAL ADJUSTED EBITDA	$             (1,926,806)	$              7,911,421
Weighted average number of common shares outstanding - basic & diluted	63,110,849	42,876,608
ADJUSTED EBITDA per share - basic & diluted	(0.03)	0.18

¹ EBITDA and Adjusted EBITDA are non-GAAP financial measures and accordingly they are not earnings measures recognized by IFRS and do not carry standard prescribed significance. Moreover, our method for calculating Adjusted EBITDA may differ from that used by other companies using the same designation.  Accordingly, we caution readers that Adjusted EBITDA should not be substituted for determining net income (loss) as an indicator of operating results or as a substitute for cash flows from operating and investing activities.

Pro forma disclosure:

The following unaudited pro forma financial information has been prepared on the assumption that the Alta, Kaya, FloraCal, and RVR acquisitions all took effect on January 1, 2018:

Unaudited Pro Forma Summary Financial Information
For the Year Ended December 31, 2018
	2018 Pro Forma (Unaudited)
2018 Acquisitions
Revenue
RVR	$                                            25,567,004
FloraCal	5,214,605
Alta	8,313,866
Kaya	2,010,941
Intercompany eliminations	(5,132,641)
Total product sales	35,973,775
Corporate
Services	757,350
Royalties	370,413
Interest income	301,167
Other income	14,226
Total revenues	$                                            37,416,931
Cost of sales^1	(33,290,672)
Gross margin	4,126,259
Gross margin percentage	11%
Operating expenses	47,350,447
Loss from operations	43,224,188
Other income	(24,793,173)
Income tax expense (recovery)	(1,638,559)
Net income (loss)	$                                           (16,792,456)

Note 1: excluding fair value impacts from IAS 41 – Agriculture (Biological Assets) applicable to FloraCal prior to acquisition.

	2018 Pro Forma (Unaudited)
Add (Subtract)
Net loss for the period	$                                           (16,792,456)
Depreciation of property and equipment	912,961
Amortization of intangible assets	6,136,840
Amortization of royalty investments	848,811
Interest expense	3,536,518
Interest income	(301,369)
Current income taxes	313,243
Deferred income tax recovery	(1,951,802)
EBITDA	(7,297,254)
Gain on investments	-
Additional expense related to letter of intent transactions	-
Bad debt expense – Cascadia royalties	-
Gain on sale of equipment	(24,672)
Gain on settlement of interests at acquisition	(1,096,189)
Impairment (recovery) of convertible notes receivable	(4,146)
Impairment of intangible assets & goodwill	-
Disposal of intangible assets	159,032
Impairment of loans and advances	359,947
Impairment of royalty investments	-
Post combination remuneration	354,266
Realized fair value amounts included in inventory sold	2,028,238
Unrealized fair value gain on growth of biological assets	(1,611,617)
Impairment (recovery) on Achelois Inventory	(441,871)
Share-based compensation	5,228,103
Transaction costs on acquisitions	536,840
Unrealized loss on embedded derivatives	-
TOTAL ADJUSTED EBITDA	$                                             (1,809,323)

The following is a summary of pro forma revenues from the 2018 acquisitions, corporate, as well as the 2019 acquisition of 180 Smoke.

180 Smoke - 2019 acquisition	$                                            11,301,065
2018 acquisitions and corporate (see above)	37,416,931
	$                                            48,717,996

Share Capital

The Company's authorized share capital is an unlimited number of common shares of which 60,263,768 were issued and outstanding as at December 31, 2018 (December 31, 2017 – 43,898,445 common shares). Also issued were 3,431,210 RSUs that have not been exercised as at December 31, 2018 including 2,551,839 that have vested (December 31, 2017 – 4,153,150 including 1,933,587 that had vested). As of December 31, 2018, there are share purchase warrants and broker warrants outstanding that can potentially be converted to 12,938 shares (December 31, 2017 – 4,112,712). The Company has issued 929,000 share options that have not been exercised as at December 31, 2018 including 420,125 that have vested (December 31, 2017 – 850,000 including 212,500 that had vested).  The Company has convertible debt which can be converted into 3,034,080 common shares (December 31, 2017 – 750,000).  The Company has issued 35,088 Class A Compressed Shares and 21,001 RPE shares which can each be converted into 100 common shares, or a total of 5,608,900 common shares (December 31, 2017 – nil).  There are an additional 35,088 Class A Compressed Shares that can be issued upon meeting certain milestones and 49,000 RPE shares that may be issued over the next 24 months. 

Conference Call

Origin House will host a conference call on, Monday, April 29, 2019, at 8:30 a.m. (Eastern Time) to discuss its fourth quarter and year ended 2018 financial results. The call will be chaired by Marc Lustig, Chief Executive Officer, Afzal Hasan, President and General Counsel and François Perrault, Chief Financial Officer.

	Participant Dial-in	Webcast	Reference Number
Conference Call	416-764-8688 or 1-888-390-0546	https://bit.ly/2Il3dJj	09173462
Replay (available for 2 weeks)	416-764-8677 or 1-888-390-0541		173462

About Origin House

Origin House is a growing cannabis brands and distribution company operating across key markets in the U.S. and Canada, with a strategic focus on becoming a preeminent global house of cannabis brands. Origin House's foundation is in California, the world's largest regulated cannabis market, where it delivers over 130 branded cannabis products from 50+ brands to the majority of licensed dispensaries. Origin House's brand development platform is operated out of five licensed facilities located across California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners. Origin House is actively developing infrastructure to support the proliferation of its brands internationally, initially through its acquisition of Canadian retailer 180 Smoke. Origin House's shares trade on the CSE under the symbol "OH" and on the OTCQX under the symbol "ORHOF". Origin House is the registered business name of CannaRoyalty Corp. For more information, visit www.originhouse.com. 

Forward Looking Statements

This press release contains "forward-looking information" under the provisions of applicable Canadian securities legislation, concerning the business, operations and financial performance and condition of the Company. Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Origin House's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should" or the negatives or variations of any of the foregoing terms and similar expressions, are intended to identify such forward-looking information.

Forward-looking information may include, without limitation, statements about the Company's (including the Company's investees and subsidiaries) plans, prospects, position, future results, and business strategies; the acquisition of the Company by Cresco Labs (the "Cresco Labs Acquisition") and any anticipated benefits thereof; the anticipated timing and completion of the Cresco Labs Acquisition; the ability of the Company to complete the transactions contemplated by the Cresco Labs Acquisition; the Company's timing and process for expansion in Canada and globally; new opportunities; future growth and other statements.

Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors and risks that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under US federal law; changes in laws; the Canadian and US regulatory landscapes and enforcement related to cannabis, including political risks and risks relating to regulatory changes; changes in general economic, business and political conditions, including changes in the financial markets; compliance with extensive government regulation; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; the risk that the Cresco Labs Acquisition will not be completed on the terms set out in the Sale Agreement, or at all; the risk that the conditions to the Cresco Labs Acquisition will not be satisfied on a timely basis or at all and the failure of the transaction to be consummated for any other reason; competitive responses to the announcement of the Cresco Labs Acquisition; actions that may be taken by Cresco Labs or by its security holders in respect of the Cresco Labs Acquisition; and other risks and uncertainties, including but not limited to those described in the "Risk Factors" section of the Company's management's discussion and analysis for the year ended December 31, 2018, which is available on SEDAR at www.sedar.com under the Company's profile. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information in this news release is made as of the date of this release. The Company disclaims any intention or obligation to update or revise such information, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE Origin House

For further inquiries, please contact: Marc Lustig, Chairman and CEO, [email protected], 1-844-556-5070, www.originhouse.com; Jonathan Ross, CFA, LodeRock Advisors Inc., [email protected], 416-283-0178